Results 21 to 30 of about 755,616 (163)
MOESM7 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
, 2019 Additional file 7: Figure S7. Gating strategy for B-cell subsets in mice. Representative gating strategy used for mice experiments for the identification of GC B-cells (CD19+CD95+IgDlow), IgA GC B-cells (CD19+CD95+IgDlowIgA+), plasma cells (CD19lowCD138+) and IgA+ plasma cells (CD19lowCD138+IgA+).Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam +13 moreopenaire +1 more sourceDiscovery of AS-1763:
A Potent, Selective, Noncovalent,
and Orally Available Inhibitor of Bruton’s Tyrosine Kinase
, 2021 Although
Bruton’s tyrosine kinase (BTK) has been recognized
as a validated drug target for the treatment of B-cell malignances,
the emergence of clinical resistance to the first-generation covalent
BTK inhibitors is becoming a serious concern.Masaaki Sawa (5801243), Takao Kiyoi (5801234), Shigeki Kashimoto (2444041), Takayuki Irie (2438509), Tokiko Asami (5801231), Hatsuo Furuichi (11441747), Wataru Kawahata (5801228) +6 morecore +1 more sourceMOESM10 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
, 2019 Additional file 10: Table S1. Overview of antibodies used for experiments.Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam +13 moreopenaire +1 more sourceMOESM11 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
, 2019 Additional file 11: Methods S1. Procedures of mouse experiments.Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam +13 moreopenaire +1 more sourceMOESM6 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
, 2019 Additional file 6: Figure S6. Autoreactive IgG and IgM does not correlate with disease progression. Fluorescence intensity for plasma autoreactive IgG (A) and IgM (B) does not correlate with decline in forced vital capacity (FVC) over 1-year period in IPF patients. Correlation coefficients were calculated using Spearmanâ s rank method.Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam +13 moreopenaire +1 more sourceMOESM9 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
, 2019 Additional file 9:. Graphic summary of B-cell subset alterations and autoreactive IgA induction in IPF patients. Immature B cells leave the bone marrow as transitional B-cells for further differentiation. Decrease in circulating transitional B-cells together with their increase in IPF lungs suggest homing towards pulmonary tertiary lymphoid organs (TLO)Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam +13 moreopenaire +1 more sourceMOESM1 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
, 2019 Additional file 1: Figure S1. No changes of proportions of total B-cells between controls and IPF patients. Flow cytometric quantification of total B-cells (CD19+) in blood, lungs and lymph nodes (LN) as percentage of alive cells. For blood samples data also depicted as absolute number of B-cells per ml blood.Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam +13 moreopenaire +1 more sourceSupplemental_Material_Covalent_BTK_by_Harris,_et_al – Supplemental material for Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase
, 2018 Supplemental material, Supplemental_Material_Covalent_BTK_by_Harris,_et_al for Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase by Christopher M. Harris, Sage E. Foley, Eric R.Mark Michalak (5510279), Noel S. Wilson (2717011), Christopher M. Harris (1463575), Eric R. Goedken (2221618), Sara Murdock (5510285), Sage E. Foley (5510282) +5 morecore +1 more sourcesj-docx-1-msj-10.1177_13524585231192460 – Supplemental material for Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
, 2023 Supplemental material, sj-docx-1-msj-10.1177_13524585231192460 for Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor by Amit Bar-Or, Anne H Cross, Anthony Elise E Drouin (16904347), Anne H Cross (5510375), Anthony L Cunningham (16904341), Andrea Seitzinger (16080114), Hans Gühring (16904344), Davorka Tomic (6679859), Nektaria Alexandri (5919553), Yann Hyvert (6856952), Amit Bar-Or (618298), Xavier Montalban (5429) +9 morecore +1 more source